We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Cancer cachexia in adult patients: ESMO Clinical Practice Guidelines <sup>☆</sup> .
- Authors
Arends, J; Strasser, F; Gonella, S; Solheim, T S; Madeddu, C; Ravasco, P; Buonaccorso, L; de van der Schueren, M A E; Baldwin, C; Chasen, M; Ripamonti, C I; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org
- Abstract
Disclosure FS reports receipt of unrestricted industry grants to institute for clinical research from Celgene, Fresenius and Helsinn, participation in company-led clinical cachexia trials for Novartis and participation in an advisory role for Helsinn, Mundipharma, Novartis, Fresenius and Kaiku Health (reimbursements to institute); TSS reports receipt of honoraria from Fresenius Kabi; MC reports receipt of payment from Tetra Biopharmaceuticals for helping to write research protocols; JA reports receipt of consultancy fees from Baxter and Danone and honoraria from Berg-Apotheke, Falk, Fresenius Kabi, Nutricia and Roche; CIR reports receipt of funding for independent educational events from Inpharm, Kyowa Kirin, Amgen Europe and Molteni SpA; MAEdvdS reports receipt of honoraria for independent lectures at educational and scientific events organised by Nutricia, Fresenius Kabi and Baxter; all other authors have declared no conflicts of interest.
- Publication
ESMO open, 2021, Vol 6, Issue 3, p100092
- ISSN
2059-7029
- Publication type
Journal Article
- DOI
10.1016/j.esmoop.2021.100092